Moleculin Biotech

147 articles with Moleculin Biotech

• Moleculin Commences Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases

  5/25/2021

  - Annamycin was designed to potentially become the first ever non-cardiotoxic anthracycline and has been shown in animal models to accumulate in the lungs at more than 30 times the level of doxorubicin (current standard of care) - Patient enrollment on track to begin this quarter - Interim data expected in the second half of 2022

• Moleculin Reports First Quarter 2021 Financial Results and Provides Programs Update

  5/12/2021

  - Multiple ongoing clinical studies expected to drive key clinical and regulatory milestones throughout next 18 months - - Significantly strengthened financial position extends cash runway through 2023 -

• Moleculin Biotech to Present at the Q2 Virtual Investor Summit

  5/11/2021

  Live video webcast with President and CEO, Walter Klemp, on Monday, May 17, 2021 at 12:30 PM ET

• Moleculin Awarded New Rare Pediatric Disease Designation from U.S. FDA for WP1066 for the Treatment of Ependymoma

  4/14/2021

  Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPD)

• Moleculin Engages IQVIA to Manage Potential COVID-19 Clinical Trial

  4/6/2021

   Moleculin Biotech, Inc., today announced the engagement of IQVIA Biotech, a contract research organization (CRO) to manage the Company's effort to begin potential clinical trials of WP1122 for the treatment of COVID-19.

• Moleculin Receives FDA Approval of Fast Track Designation for Annamycin in the Treatment of Sarcoma Lung Metastases

  3/30/2021

   Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the U.S. Food and Drug Administration ("FDA") has approved its request for Fast Track Designation for its drug, Annamycin,

• Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2020

  3/24/2021

   Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its financial results for the year ended December 31, 2020 and provided a business update.

• Moleculin to Participate in Four Upcoming Healthcare Conferences

  3/9/2021

  Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that members of management will be presenting at four upcoming healthcare conferences.

• Moleculin Announces Full Exercise of Over-Allotment Option

  2/10/2021

  Moleculin Biotech, Inc.,today announced that the underwriters of its public offering announced February 3, 2021 have exercised in full their option to purchase an additional 2,141,052 shares of common stock

• Moleculin Announces Grant Awarded to Polish Research Institute for Independent Clinical Trial of Annamycin in Sarcoma Lung Metastases

  2/8/2021

   Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the Agencja Badań Medycznych, awarded a grant equivalent to $1.5 million USD to the Maria Sklodowska-Curie National Research Institute to fund a Phase 1B/2 clinical trial of Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases. 

• Moleculin Announces Pricing Of $67.8 Million Underwritten Public Offering

  2/3/2021

  Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the pricing of an underwritten public offering of an aggregate of 14,273,684 shares of common stock at a public offering price of $4.75 per share

• Moleculin Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model

  2/2/2021

  Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that a preclinical study in animals demonstrated a potentially significant therapeutic benefit of Annamycin against metastatic osteosarcoma.

• Moleculin Announces Proposed Underwritten Public Offering - Feb 02, 2021

  2/2/2021

  Moleculin Biotech, Inc., a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced that it intends to offer and sell shares of common stock in an underwritten public offering.

• Moleculin Signs Agreement with Catalyst Clinical Research to Begin Sarcoma Trial

  2/1/2021

   Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it has signed an agreement with Catalyst Clinical Research (Catalyst), a contract research organization, to manage its US clinical trial to study the ability of Annamycin to treat soft tissue sarcoma (STS) that has metastasized to the lungs.

• Moleculin Announces Reverse Stock Split

  1/29/2021

  Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it filed a certificate of amendment to its certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-6 reverse stock split of its common stock.

• Moleculin to Present at the H.C. Wainwright BioConnect 2021 Conference

  1/7/2021

   Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that members of management will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 202

• Moleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

  12/29/2020

  Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Annamycin for treatment of soft ti

• Moleculin Announces FDA Permission to Begin Clinical Study of Annamycin for Sarcoma Lung Metastases

  12/17/2020

  Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) is allowing the company's Investigational New Drug (IND) application to study Annamycin for the treatment of soft tissue sarcoma lung metastases to go into effect

• Moleculin To Present Antitumor Activity of Annamycin in Combination with Ara-C in AML at American Society for Hematology Annual Conference

  12/3/2020

   Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it will present animal data demonstrating highly improved activity against acute myeloid leukemia ("AML") in combination w

• 

  FDA Works to Get New Drugs to Patients Faster with Multiple Approvals This Week

  12/2/2020

  The FDA uses special designations to get new, breakthrough treatments to patients in the greatest need.